It may be too early to say but a recent medical effort to develop a vaccine to cancer is showing promising results in its early phase, multiple reports said.
“The new treatment is designed to stimulate the immune system into attacking certain cancers known to overexpress a specific protein,”said an AtlasNews report, referring to a protein called HER2 or Human Epidermal Growth Factor Receptor 2.
Breastcancer.org defined HER2 as a gene that plays a role on the development of breast cancer. This usually help control healthy breast cells, which unfortunately does not work in about 25 percent of the time. When HER 2 gene does not work, the report added, it “makes breast cells grow and divide in an uncontrolled way.”
“The new vaccine is customized to each individual patient, with immune cells collected and then modified before being administered back intradermally. The cells derived from each patient are engineered with parts of the HER2 protein combined with an adenovirus so when they are re-administered they hopefully train the immune system to attack the HER2-expressing tumors,” a report said.
ScienceDaily.com said six out of the 11 patients who received the vaccine in its lowest dose, “had clinical benefits.”
“One patient with ovarian cancer had a complete response that lasted 89 weeks, one patient with gastroesophageal cancer had a partial response that lasted 16 weeks, and four patients (two with colon cancer, one with prostate cancer, and one with ovarian cancer) had stable disease,” the report said.
Jay Berzofsky, chief of the Vaccine Branch at the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland said they hope to “provide a new treatment option for patients with these cancers.”
NewAtlas said there are plenty of research seeking to find an immunotherapy agent to attack the tumors more effectively. Last month, a group of medical experts have successfully developed a vaccine against a type of skin cancer on a mice model.
Berzofsky added that they would also like to “investigate whether we can increase the proportion of people who benefit from treatment with the vaccine by combining it with checkpoint inhibitor therapy.”